Progyny (PGNY)
(Delayed Data from NSDQ)
$16.10 USD
-0.35 (-2.13%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $16.10 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
B Value A Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.10 USD
-0.35 (-2.13%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $16.10 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
B Value A Growth C Momentum A VGM
Zacks News
Progyny (PGNY) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Progyny (PGNY) delivered earnings and revenue surprises of 160% and 5.64%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ELV or PGNY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ELV vs. PGNY: Which Stock Is the Better Value Option?
Progyny (PGNY) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Progyny (PGNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AMN or PGNY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMN vs. PGNY: Which Stock Is the Better Value Option?
MODV vs. PGNY: Which Stock Is the Better Value Option?
by Zacks Equity Research
MODV vs. PGNY: Which Stock Is the Better Value Option?
Does Progyny (PGNY) Have the Potential to Rally 64% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 63.5% in Progyny (PGNY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
MODV vs. PGNY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MODV vs. PGNY: Which Stock Is the Better Value Option?
Can Progyny (PGNY) Climb 47% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 46.6% in Progyny (PGNY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
AMN vs. PGNY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AMN vs. PGNY: Which Stock Is the Better Value Option?
Progyny (PGNY) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Progyny (PGNY) delivered earnings and revenue surprises of 350% and 2.24%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Molina Healthcare (MOH) to Buy My Choice Wisconsin for $150M
by Zacks Equity Research
Molina Healthcare (MOH) expects the buyout to complement its existing Medicaid business in Wisconsin.
Encompass Health (EHC) to Build New Rehab Unit in Missouri
by Zacks Equity Research
Encompass Health (EHC) and BJC HealthCare's new rehabilitation hospital is expected to come online in 2024.
Progyny (PGNY) Upgraded to Buy: Here's Why
by Zacks Equity Research
Progyny (PGNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
CoDiagnostics, Inc. (CODX) Surges 5.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
CoDiagnostics, Inc. (CODX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Will Mednax's (MD) New Name Pediatrix Medical be Beneficial?
by Zacks Equity Research
Mednax's (MD) name change is expected to take effect following the closing bell on Jul 1, 2022.
UnitedHealth (UNH) Unit Eyes $1.5B EMIS Acquisition in UK
by Zacks Equity Research
UnitedHealth's (UNH) Optum business operates in the United Kingdom for two decades and the acquisition is expected to boost its footprint in the country.
HCA Healthcare (HCA) Scraps Utah Buyout Post FTC's Roadblock
by Zacks Equity Research
HCA Healthcare's (HCA) aborted acquisition follows another abandoned buyout plan involving RWJBarnabas Health and Saint Peter's Healthcare System.
Centene (CNC) Raises 2022 Guidance, Ups Share Buyback Fund
by Zacks Equity Research
Currently, Centene (CNC) has $3.6 billion remaining under its share buyback program.
Cigna (CI) Signs $3.5B Accelerated Share Buyback Agreements
by Zacks Equity Research
Cigna (CI) intends to buy back at least $7 billion worth of its stocks this year alone.
Encompass Health (EHC) Forms JV With NCH Healthcare in Naples
by Zacks Equity Research
The NCH Healthcare System's board grants approval to invest in the joint venture with Encompass Health (EHC).
Encompass Health (EHC) Plans to Distribute Enhabit Shares
by Zacks Equity Research
Every Encompass Health (EHC) shareholder will receive one Enhabit common share for every two EHC common shares held.
Should You Hold On to Teladoc Health (TDOC) Stock for Now?
by Zacks Equity Research
Teladoc Health's (TDOC) cash flows will likely gain from the growing number of visits and memberships.
HCA Healthcare's (HCA) Galen College Adds 8th New Facility
by Zacks Equity Research
HCA Healthcare's (HCA) Galen College nursing campus addition comes when the country is suffering from a nursing shortage.
AMN or PGNY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMN vs. PGNY: Which Stock Is the Better Value Option?
Here's Why Investors Should Bet on Cigna (CI) Stock Now
by Zacks Equity Research
Cigna (CI) expects 2022 medical customers to grow by a minimum of 725,000, suggesting an upside from the prior projection.